In contrast with the previous thought of KRAS mutant independency from upstream RTK, recent data demonstrate that the genetic abrogation of EGFR resulted in impaired tumor growth of KRAS mutant NSCLC models. This evidence concerns the gene EGFR and non-small cell lung carcinoma.